Boryung Corporationfounded In 1957 And Headquartered In Seoulsouth Koreais A Healthcare And Pharmaceutical Company That Has Evolved From A Local Pharmacy Into A Significant Player In The Industryoriginally Known As Boryung Pharmaceuticalthe Company Rebranded To Boryung Corpin March 2022 To Reflect Its Broader Focus Beyond Traditional Pharmaceuticalsin 2023Boryung Reported Revenues Of $617 21 Million And A Gross Profit Of $253 76 Million Boryung Develops And Manufactures A Range Of Pharmaceuticalsincluding Kanarbsouth Korea S First Arb Antihypertensive Medicationthe Company Also Invests In Innovative Medical Technologies And Has Formed Strategic Partnershipsnotably With Axiom Spaceto Advance Healthcare Initiatives In Spacetheir Joint Venturebrax Space Corporationfocuses On Low Earth Orbit Commercialization And Research For Space Based Health Solutionsboryung Is Committed To Contributing To Human Healthextending Its Legacy Into Emerging Sectors Like Space Medicine
